Related Experiment Video
Updated: Jun 8, 2026
03:53
Extracellular Vesicle Tissue Factor Activity Assay
Published on: December 29, 2023
Tissue factor in cardiovascular disease pathophysiology and pharmacological intervention
1Cardiovascular Research, Physiology Institute, University of Zurich, Zurich, Switzerland.
Advances in Pharmacology (San Diego, Calif.)
|October 12, 2010
Summary
Tissue factor (TF) triggers blood clotting and is implicated in cardiovascular disease and cancer. Inhibiting TF offers a potential therapeutic strategy for these conditions.
Area of Science:
- Biochemistry
- Vascular Biology
- Oncology
Background:
- Tissue factor (TF) initiates the coagulation cascade, essential for hemostasis.
- TF is expressed in vascular cells and circulating cells, and its activity can be induced.
- TF also acts as a receptor, mediating intracellular signaling involved in cell proliferation and migration.
Purpose of the Study:
- To review the role of tissue factor in hemostasis, cardiovascular disease, and cancer.
- To explore TF as a therapeutic target for cardiovascular diseases and cancer.
- To discuss strategies for TF inhibition and their clinical implications.
Main Methods:
- Literature review of TF's role in coagulation and disease.
- Analysis of TF's extracellular and intracellular functions.
- Examination of TF inhibition strategies and clinical trial considerations.
Main Results:
- TF is a critical initiator of coagulation and is involved in neointima formation, tumor growth, and cardiovascular risk.
- Increased TF levels are observed in patients with cardiovascular disease and cancer.
- TF inhibition strategies include blocking synthesis or action, with ongoing research into targeted delivery.
Conclusions:
- Tissue factor plays a dual role in hemostasis and pathological processes like cardiovascular disease and cancer.
- Targeting TF presents a promising therapeutic avenue for these conditions.
- Further clinical trials are necessary to evaluate the efficacy and delivery methods of TF inhibitors.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...